Indoco Remedies (NSE:INDOCO) Beta: 1.9462 (As of Jun. 28, 2026)


NSE:INDOCO Indoco Remedies Ltd NSE:INDOCO
66 GF Score
Price ₹231.60
GF Value ₹358.97
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Indoco Remedies Beta?

Indoco Remedies NSE:INDOCO -2.36% 66 Beta is 1.9462 as of Jun. 28, 2026. GuruFocus rates NSE:INDOCO with a GF Score™ of 66/100 and a GF Value™ of ₹358.97 (Possible Value Trap). The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-28), Indoco Remedies's Beta is 1.9462.


Indoco Remedies  (NSE:INDOCO) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Indoco Remedies Beta Related Terms


Indoco Remedies Beta Historical Data

* Premium members only.

The historical data trend for Indoco Remedies's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indoco Remedies Beta Chart

Indoco Remedies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.52 0.78 1.08 1.49 1.78

Indoco Remedies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.49 1.77 2.00 1.99 1.78

NSE:INDOCO vs ZTS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Indoco Remedies's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Indoco Remedies Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Indoco Remedies's Beta distribution charts can be found below:

* The bar in red indicates where Indoco Remedies's Beta falls into.


NSE:INDOCO
66GF Score
Indoco Remedies Ltd NSE:INDOCO
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indoco Remedies Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.9462 mean?
Indoco Remedies (NSE:INDOCO) has a Beta of 1.9462 as of Jun. 28, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Indoco Remedies and its competitors.
Is Indoco Remedies' Beta too high?
Indoco Remedies' current Beta is 1.9462. Overall, Indoco Remedies has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indoco Remedies' Beta compare to ZTS?
Indoco Remedies' Beta of 1.9462 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Indoco Remedies and its competitors. Indoco Remedies's current Beta is 1.9462. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indoco Remedies stock overvalued right now?
Based on GuruFocus' analysis, Indoco Remedies (NSE:INDOCO) is currently considered Possible Value Trap. The stock's GF Value™ is ₹358.97, compared to a current price of ₹231.60 — trading 35.5% below its estimated fair value. The current Beta is 1.9462. Indoco Remedies' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Indoco Remedies (NSE:INDOCO), the current Beta is 1.9462 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indoco Remedies (NSE:INDOCO) Overvalued in 2026?

Based on GuruFocus' analysis, Indoco Remedies stock appears to be undervalued. The current stock price of ₹231.60 is trading 35.5% below its estimated GF Value™ of ₹358.97. GuruFocus considers Indoco Remedies to be Possible Value Trap.

Key valuation signals for NSE:INDOCO:

  • Beta: 1.9462
  • GF Value™: ₹358.97 vs. price of ₹231.60 (35.5% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the NSE:INDOCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Indoco Remedies Business Description

Other Exchanges 532612:India
Address 166 CST Road, Indoco House, Kalina, Santacruz (East), Mumbai, MH, IND, 400 098
Indoco Remedies Ltd is an India-based pharmaceutical company. The company is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The company manufactures products for different therapeutic sectors including Gastroenterology, Dentistry & Stomatology, Respiratory, Diabetology, Women's Health, Nutritional products, Cardiology, Metabolic Disorders, and Primary Care medicines. The only operating segment of the company is Pharmaceutical Products. Geographically, it generates the majority of the revenue from India.
66GF Score

Get the complete analysis for NSE:INDOCO

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹231.60
Price
₹358.97
GF Value